<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Semaglutide API – Technical profile</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <style>
    :root {
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      line-height: 1.5;
      color: #111827;
      background-color: #f9fafb;
    }

    body {
      margin: 0;
      padding: 24px;
    }

    .api-profile {
      max-width: 1080px;
      margin: 0 auto;
      background: #ffffff;
      border-radius: 16px;
      padding: 24px 24px 32px;
      box-shadow: 0 10px 30px rgba(15, 23, 42, 0.08);
      border: 1px solid #e5e7eb;
    }

    .api-profile__label {
      text-transform: uppercase;
      font-size: 11px;
      letter-spacing: 0.12em;
      font-weight: 600;
      color: #6b7280;
      margin-bottom: 4px;
    }

    .api-profile__title {
      font-size: 24px;
      font-weight: 700;
      margin: 0 0 8px;
      color: #111827;
    }

    .api-profile__subtitle {
      font-size: 14px;
      color: #4b5563;
      margin-bottom: 16px;
    }

    .api-profile__grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
      gap: 12px 24px;
      margin-bottom: 16px;
    }

    .fact {
      font-size: 13px;
    }

    .fact__label {
      font-size: 11px;
      text-transform: uppercase;
      letter-spacing: 0.08em;
      color: #9ca3af;
      margin-bottom: 2px;
    }

    .fact__value {
      font-weight: 500;
      color: #111827;
    }

    .tag-list {
      display: flex;
      flex-wrap: wrap;
      gap: 6px;
      margin: 8px 0 16px;
    }

    .tag {
      font-size: 11px;
      padding: 4px 8px;
      border-radius: 999px;
      background: #f3f4f6;
      color: #374151;
      border: 1px solid #e5e7eb;
      white-space: nowrap;
    }

    .pill-section-title {
      font-size: 13px;
      font-weight: 600;
      color: #6b7280;
      margin-top: 8px;
      margin-bottom: 4px;
    }

    .bullet-list {
      margin: 0;
      padding-left: 18px;
      font-size: 13px;
      color: #111827;
    }

    .bullet-list li {
      margin-bottom: 4px;
    }

    .api-sections {
      margin-top: 24px;
      border-top: 1px solid #e5e7eb;
      padding-top: 8px;
    }

    .api-section {
      border-radius: 12px;
      border: 1px solid #e5e7eb;
      margin-top: 12px;
      overflow: hidden;
      background: #f9fafb;
    }

    .api-section__header {
      width: 100%;
      display: flex;
      align-items: center;
      justify-content: space-between;
      padding: 10px 14px;
      background: #f3f4f6;
      border: none;
      outline: none;
      cursor: pointer;
    }

    .api-section__title {
      display: flex;
      flex-direction: column;
      align-items: flex-start;
      gap: 2px;
    }

    .api-section__title h3 {
      margin: 0;
      font-size: 14px;
      font-weight: 600;
      color: #111827;
    }

    .api-section__hint {
      font-size: 12px;
      color: #9ca3af;
    }

    .api-section__icon {
      font-size: 18px;
      color: #9ca3af;
      transition: transform 0.15s ease;
    }

    .api-section--open .api-section__icon {
      transform: rotate(90deg);
    }

    .api-section__body {
      display: none;
      padding: 12px 14px 14px;
    }

    .api-section--open .api-section__body {
      display: block;
    }

    .api-section__summary {
      font-size: 13px;
      color: #374151;
      margin: 0 0 8px;
    }

    .api-section__details p {
      font-size: 13px;
      color: #111827;
      margin: 0 0 8px;
    }

    .table-wrapper {
      width: 100%;
      overflow-x: auto;
      margin-top: 8px;
    }

    table {
      border-collapse: collapse;
      width: 100%;
      font-size: 12px;
      min-width: 420px;
    }

    th,
    td {
      border: 1px solid #e5e7eb;
      padding: 6px 8px;
      text-align: left;
      vertical-align: top;
    }

    th {
      background: #f3f4f6;
      font-weight: 600;
      font-size: 11px;
      text-transform: uppercase;
      letter-spacing: 0.06em;
      color: #6b7280;
    }

    @media (max-width: 640px) {
      body {
        padding: 12px;
      }

      .api-profile {
        padding: 16px 14px 20px;
      }

      .api-profile__title {
        font-size: 20px;
      }
    }
  </style>
</head>
<body>
  <section class="api-profile" id="api-technical-profile">
    <!-- KEY FACTS (always visible) -->
    <div class="api-profile__label">API technical profile</div>
    <h2 class="api-profile__title">
      Semaglutide | CAS No: 910463-68-2 | GMP-certified suppliers
    </h2>
    <p class="api-profile__subtitle">
      GLP-1 receptor agonist used for type 2 diabetes management and chronic weight control in eligible patients.
    </p>

    <div class="api-profile__grid">
      <div class="fact">
        <div class="fact__label">Generic name</div>
        <div class="fact__value">Semaglutide</div>
      </div>
      <div class="fact">
        <div class="fact__label">Molecule type</div>
        <div class="fact__value">Small molecule (peptide-like)</div>
      </div>
      <div class="fact">
        <div class="fact__label">CAS</div>
        <div class="fact__value">910463-68-2</div>
      </div>
      <div class="fact">
        <div class="fact__label">DrugBank ID</div>
        <div class="fact__value">DB13928</div>
      </div>
      <div class="fact">
        <div class="fact__label">Approval status</div>
        <div class="fact__value">Approved drug, investigational</div>
      </div>
      <div class="fact">
        <div class="fact__label">ATC</div>
        <div class="fact__value">A10BJ06 – GLP-1 analogues</div>
      </div>
    </div>

    <div class="pill-section">
      <div class="pill-section-title">Therapeutic categories</div>
      <div class="tag-list">
        <span class="tag">Drugs used in diabetes</span>
        <span class="tag">GLP-1 receptor agonist</span>
        <span class="tag">Blood glucose lowering agents</span>
        <span class="tag">Gastrointestinal hormones</span>
      </div>

      <div class="pill-section-title">Primary indications (high level)</div>
      <ul class="bullet-list">
        <li>Improvement of glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.</li>
        <li>Chronic weight management in adults with obesity or overweight with weight-related comorbidities.</li>
        <li>Use is not intended for type 1 diabetes or diabetic ketoacidosis.</li>
      </ul>
    </div>

    <!-- COLLAPSIBLE SECTIONS -->
    <div class="api-sections">
      <!-- 1. Clinical overview & indications -->
      <article class="api-section api-section--open">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Clinical overview & indications</h3>
            <span class="api-section__hint">What this API is used for and key clinical context</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Semaglutide is a long-acting GLP-1 receptor agonist developed for once-weekly
            subcutaneous administration and once-daily oral dosing, targeting glycemic control and
            weight reduction in type 2 diabetes and obesity populations.
          </p>
          <div class="api-section__details">
            <p>
              Semaglutide is indicated to improve glycemic control in adults with type 2 diabetes mellitus
              as an adjunct to diet and exercise. It is not used in type 1 diabetes, diabetic ketoacidosis,
              or as initial therapy when lifestyle modification alone may suffice. The molecule also carries
              regulatory approvals for chronic weight management in adults with obesity or overweight with at
              least one weight-related comorbidity, and in defined pediatric populations.
            </p>
            <p>
              Clinically, semaglutide has demonstrated robust reductions in HbA1c, fasting plasma glucose,
              body weight and selected cardiovascular risk markers across multiple phase 3 trial programs.
            </p>
          </div>
        </div>
      </article>

      <!-- 2. Identification & classification -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Identification & classification</h3>
            <span class="api-section__hint">How the molecule is named, coded and classified</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Semaglutide is a polypeptide-based GLP-1 analogue classified under A10BJ06 and
            belongs to the broader class of organic polypeptides used in diabetes management.
          </p>
          <div class="api-section__details">
            <div class="table-wrapper">
              <table>
                <thead>
                  <tr>
                    <th colspan="2">Identification</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Generic name</td>
                    <td>Semaglutide</td>
                  </tr>
                  <tr>
                    <td>Synonyms</td>
                    <td>Semaglutide; Sémaglutide</td>
                  </tr>
                  <tr>
                    <td>Molecule type</td>
                    <td>Small molecule (peptidic)</td>
                  </tr>
                  <tr>
                    <td>Groups</td>
                    <td>Approved; Investigational</td>
                  </tr>
                  <tr>
                    <td>CAS</td>
                    <td>910463-68-2</td>
                  </tr>
                  <tr>
                    <td>UNII</td>
                    <td>53AXN4NNHX</td>
                  </tr>
                  <tr>
                    <td>DrugBank ID</td>
                    <td>DB13928</td>
                  </tr>
                </tbody>
              </table>
            </div>

            <div class="table-wrapper" style="margin-top: 12px;">
              <table>
                <thead>
                  <tr>
                    <th colspan="2">Regulatory classification (ATC)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>ATC code</td>
                    <td>A10BJ06 – Glucagon-like peptide-1 (GLP-1) analogues</td>
                  </tr>
                  <tr>
                    <td>Higher levels</td>
                    <td>
                      A10BJ – GLP-1 analogues<br />
                      A10B – Blood glucose lowering drugs, excl. insulins<br />
                      A10 – Drugs used in diabetes<br />
                      A – Alimentary tract and metabolism
                    </td>
                  </tr>
                  <tr>
                    <td>Chemical class</td>
                    <td>
                      Kingdom: Organic compounds<br />
                      Superclass: Organic polymers<br />
                      Class: Polypeptides<br />
                      Direct parent: Polypeptides
                    </td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>
      </article>

      <!-- 3. Pharmacology & targets -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Pharmacology & targets</h3>
            <span class="api-section__hint">Mechanism of action, pharmacodynamics and key targets</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Semaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin
            secretion, suppresses glucagon, slows gastric emptying and modulates appetite,
            contributing to glycemic control, weight reduction and cardiometabolic benefits.
          </p>
          <div class="api-section__details">
            <h4 style="font-size:13px; margin: 4px 0 4px;">Mechanism of action</h4>
            <p>
              GLP-1 is a physiological hormone that promotes glycemic control via increased insulin
              secretion, slowed gastric emptying and reduced postprandial glucagon secretion.
              Semaglutide shares high sequence homology with native GLP-1 and selectively activates
              the GLP-1 receptor, stimulating pancreatic islet cells to increase insulin synthesis
              and reduce inappropriate glucagon release in a glucose-dependent fashion.
            </p>

            <h4 style="font-size:13px; margin: 8px 0 4px;">Pharmacodynamics</h4>
            <p>
              Treatment with semaglutide lowers HbA1c, fasting and postprandial plasma glucose,
              reduces body weight and modestly improves triglycerides and VLDL cholesterol.
              Safety-relevant pharmacodynamic effects include delayed gastric emptying,
              which may influence the absorption of concomitantly administered oral drugs.
            </p>

            <div class="table-wrapper">
              <table>
                <thead>
                  <tr>
                    <th>Target</th>
                    <th>Organism</th>
                    <th>Action</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Glucagon-like peptide 1 receptor (GLP-1R)</td>
                    <td>Human</td>
                    <td>Agonist</td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>
      </article>

      <!-- 4. ADME / PK -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>ADME / PK profile</h3>
            <span class="api-section__hint">Absorption, distribution, metabolism and elimination</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Long half-life (~168 h) driven by strong albumin binding allows once-weekly
            dosing of injectable semaglutide and supports sustained plasma exposure.
          </p>
          <div class="api-section__details">
            <ul class="bullet-list">
              <li>Oral bioavailability is low but enhanced through specialized formulations.</li>
              <li>More than 99% bound to plasma albumin, leading to low clearance.</li>
              <li>Half-life around 168 h enables once-weekly subcutaneous dosing.</li>
              <li>Eliminated primarily via renal excretion, with contributions from fecal routes.</li>
            </ul>

            <div class="table-wrapper">
              <table>
                <thead>
                  <tr>
                    <th>Parameter</th>
                    <th>Details</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Absorption</td>
                    <td>
                      Cmax ≈ 10.9 nmol/L, AUC ≈ 3123 nmol·h/L, Tmax ≈ 56 h (1–3 days).
                      Oral steady-state is reached in 4–5 weeks; absolute bioavailability
                      reported around 89% for the injectable formulation.
                    </td>
                  </tr>
                  <tr>
                    <td>Distribution</td>
                    <td>
                      Volume of distribution 8–9.4 L. More than 99% bound to albumin,
                      limiting tissue distribution and renal clearance.
                    </td>
                  </tr>
                  <tr>
                    <td>Metabolism</td>
                    <td>
                      Slowly metabolized via backbone cleavage and β-oxidation of the fatty
                      acid chain. Degradation involves DPP-4 and neutral endopeptidase with
                      multiple circulating metabolites identified.
                    </td>
                  </tr>
                  <tr>
                    <td>Half-life</td>
                    <td>Approximately 168 h (≈7 days), enabling once-weekly administration.</td>
                  </tr>
                  <tr>
                    <td>Clearance</td>
                    <td>
                      Clearance around 0.039–0.05 L/h in patients with type 2 diabetes,
                      with limited impact of hepatic impairment on overall exposure.
                    </td>
                  </tr>
                  <tr>
                    <td>Elimination</td>
                    <td>
                      Predominantly renal excretion (≈53% of a radiolabeled dose in urine),
                      with additional elimination via feces and minor exhaled fraction.
                    </td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>
      </article>

      <!-- 5. Formulation & handling -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Formulation & handling notes</h3>
            <span class="api-section__hint">Technical points for drug product development</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            High-molecular-weight peptide requiring careful control of temperature,
            agitation and gastric conditions depending on route of administration.
          </p>
          <div class="api-section__details">
            <ul class="bullet-list">
              <li>
                Semaglutide is formulated primarily as a subcutaneous aqueous solution and
                should be protected from elevated temperatures and excessive agitation to
                preserve structural integrity.
              </li>
              <li>
                Oral tablets rely on absorption enhancers and must be administered under
                controlled gastric conditions (e.g., fasting state with limited water) to
                secure reproducible exposure.
              </li>
              <li>
                Extreme hydrophilicity and low permeability shift formulation priorities
                towards maintaining peptide stability and minimizing degradation.
              </li>
            </ul>
          </div>
        </div>
      </article>

      <!-- 6. Regulatory & market landscape -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Regulatory & market landscape</h3>
            <span class="api-section__hint">Lifecycle stage, patents and availability</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Semaglutide is an approved GLP-1 analogue with a maturing patent landscape,
            marketed across major regulated markets and moving from mid- to late-lifecycle.
          </p>
          <div class="api-section__details">
            <p>
              Most listed U.S. patents on semaglutide have expired, with remaining protection
              extending into the late 2020s and at least one patent reaching into the early
              2030s. This points to a product in transition from mid- to late-lifecycle,
              with generic competition constrained by staggered IP expiry.
            </p>
            <p>
              A single originator currently supplies the API and finished products in the US,
              Canada and EU. Broader generic participation will depend on the timing and scope
              of remaining patent and exclusivity protections, as well as complex peptide
              manufacturing capabilities.
            </p>
          </div>
        </div>
      </article>

      <!-- 7. Safety & risk notes -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Safety & risk notes</h3>
            <span class="api-section__hint">Core safety considerations at API level</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Key risks include potential pancreatitis, dehydration and theoretical thyroid
            C-cell tumors, combined with a long elimination half-life requiring extended
            monitoring in overdose scenarios.
          </p>
          <div class="api-section__details">
            <ul class="bullet-list">
              <li>Overdose exposures up to 4 mg mainly caused gastrointestinal events such as nausea.</li>
              <li>No specific antidote is available; management is supportive.</li>
              <li>Elimination half-life of about one week may require prolonged observation.</li>
            </ul>
            <p>
              Product labels caution against use in patients with a personal or family history of
              medullary thyroid carcinoma, and recommend immediate medical assessment for
              signs of pancreatitis, such as persistent severe abdominal pain. Delayed gastric
              emptying may alter the absorption profile of co-administered oral medicines.
            </p>
          </div>
        </div>
      </article>

      <!-- 8. Buyer cheatsheet -->
      <article class="api-section">
        <button class="api-section__header" type="button" data-section-toggle>
          <div class="api-section__title">
            <h3>Buyer cheatsheet</h3>
            <span class="api-section__hint">Fast facts for sourcing & procurement</span>
          </div>
          <span class="api-section__icon">▶</span>
        </button>
        <div class="api-section__body">
          <p class="api-section__summary">
            Snapshot for sourcing teams evaluating semaglutide API suppliers.
          </p>
          <div class="api-section__details">
            <ul class="bullet-list">
              <li>Available as injectable peptide for subcutaneous use and as an oral peptide formulation.</li>
              <li>Used for type 2 diabetes control and chronic weight management in adults and some adolescents.</li>
              <li>Approved across major regulated markets (US, Canada, EU) with ongoing development in others.</li>
            </ul>
          </div>
        </div>
      </article>
    </div>
  </section>

  <script>
    document.querySelectorAll("[data-section-toggle]").forEach(function (btn) {
      btn.addEventListener("click", function () {
        const section = btn.closest(".api-section");
        section.classList.toggle("api-section--open");
      });
    });
  </script>
</body>
</html>
